Diffuse large B-cell lymphoma: open trials in China

133 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07200375
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Research · Hoffmann-La Roche
Peking University People's Hospital, Beijing · Peking University Third Hospital, Beijing · The First Bethune Hospital of Jilin University, Changchun · West China Hospital of Sichuan University, Chengdu · Guangdong Provincial People's Hospital, Guangzhou · Harbin Medical University Cancer Hospital, Harbin · Shandong Cancer Hospital, Jinan · Cancer Hospital Chinese Academy of Medical Sciences, Langfang · The Second Affiliated Hospital of Nanchang University, Nanchang · The First Affiliated Hospital of Ningbo University, Ningbo · Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai · Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai · Tianjin Cancer Hospital, Tianjin · Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan · Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan · The First Affiliated Hospital of Xian Jiao Tong University, Xi'an · Yantai Yu Huangding Hospital, Yantai · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-11-05
NCT07917624
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,, Beijing
Registry updated 2026-11-04
NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Beijing Cancer hospital ( Site 3000), Beijing · The First Hospital of Jilin University-Hematology ( Site 3012), Changchun · Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu · West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Chengdu · Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing · Chongqing University Three Gorges Hospital ( Site 3026), Chongqing · Zhujiang Hospital ( Site 3002), Guangzhou · Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou · Zhejiang Cancer Hospital ( Site 3014), Hangzhou · The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang · The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang · Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang · Fudan University Shanghai Cancer Center ( Site 3009), Shanghai · Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan · Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou
Registry updated 2026-11-03
NCT07908888
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
Trial Treatment · Phase 4 · The First Hospital of Jilin University
The First Hospital of Jilin University, Changchun
Registry updated 2026-11-02
NCT07260812
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 1 · TCRx Therapeutics Co.Ltd
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
Registry updated 2026-10-26
NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Beijing Cancer Hospital ( Site 3101), Beijing · Peking University Third Hospital ( Site 3102), Beijing · The First Hospital Of Jilin University ( Site 3103), Changchun · Sichuan Cancer Hospital. ( Site 3111), Chengdu · West China Hospital, Sichuan University ( Site 3110), Chengdu · Chongqing Cancer Hospital ( Site 3113), Chongqing · Fujian Provincial Cancer Hospital. ( Site 3119), Fuzhou · Sun Yat-sen University Cancer Center ( Site 3121), Guangzhou · Zhujiang Hospital of Southern Medical University ( Site 3122), Guangzhou · The Affiliated Hospital of Guizhou Medical University ( Site 3112), Guiyang · The First Affiliated Hospital, Zhejiang Medical University ( Site 3116), Hangzhou · Anhui Provincial Cancer Hospital ( Site 3124), Hefei · Shandong Cancer Hospital ( Site 3108), Jinan · Yunnan Province Cancer Hospital ( Site 3109), Kunming · LinYi Cancer Hospital ( Site 3104), Linyi · Jiangxi Cancer Hospital ( Site 3118), Nanchang · Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123), Nanning · Affiliated Hospital of Nantong University ( Site 3117), Nantong · Fudan University Shanghai Cancer Center ( Site 3115), Shanghai · Shanxi Cancer Hospital ( Site 3106), Taiyuan · Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105), Tianjin · Hubei Cancer Hospital ( Site 3125), Wuhan · The First Affiliated Hospital of Xiamen University ( Site 3120), Xiamen · 1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107), Xi’an
Registry updated 2026-10-21
NCT07012980
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Trial Treatment · Phase 2 · Shanghai Zhongshan Hospital
Zhongshan Hospital,Fudan University, Shanghai
Registry updated 2026-10-16
NCT07878351
Prospective ctDNA Testing in Large B-Cell Lymphoma
Research · Peking University People's Hospital
Peking University People's Hospital, Beijing · Beijing Tongren Hospital, Beijing
Registry updated 2026-10-16
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Trial Treatment · Phase 1 · Pfizer
Hunan Cancer Hospital, Changsha · West China Hospital，Sichuan University, Chengdu · The First Affiliated Hospital of Guangzhou Medical University, Guangzhou · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · Zhongda Hospital Southeast University, Nanjing · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Registry updated 2026-10-15
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-15
NCT07808827
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 3 · Shanghai Junshi Bioscience Co., Ltd.
Beijing Cancer Hospital, Beijing
Registry updated 2026-10-14
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Yichang Central Peoples Hospitaljiangnan Branch, Yichang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-05
NCT07818499
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-09-14
NCT06830031
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Trial Treatment · Phase 1 · Shanghai Exuma Biotechnology Ltd.
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-09-11
NCT07812493
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
Trial Treatment · Phase 2 · Pengpeng Xu
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-09-11
NCT07570017
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Trial Treatment · Phase 1 · Guangzhou Lupeng Pharmaceutical Company LTD.
Sun Yat-sen University Cancer Center, Guangzhou · Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-09-10
NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Trial Treatment · Phase 1/2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
The Second Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou, Zhejiang 310009, Hangzhou
Registry updated 2026-08-26
NCT07778212
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
Trial Treatment · The First Affiliated Hospital of Xiamen University
The First Affiliated hospital of Xiamen University, Xiamen
Registry updated 2026-08-21
NCT06792253
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 3 · BeBetter Med Inc
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Registry updated 2026-08-19
NCT07774234
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
Trial Treatment · Phase 2 · The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-08-19
NCT07764601
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
Trial Treatment · WEI XU
The First People's Hospital Of Changzhou, Changzhou · The First People's Hospital of Huai'an, Huai'an · The First Affiliated Hospital of Nanjing Medical University, Nanjing · Wuxi People's Hospital, Wuxi · Yixing People's Hospital, Yixing
Registry updated 2026-08-14
NCT07570823
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 3 · Sinocelltech Ltd.
Beijing Cancer Hospital, Beijing
Registry updated 2026-08-13
NCT07744724
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
Trial Treatment · Phase 2 · Changzhou No.2 People's Hospital
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing
Registry updated 2026-08-06
NCT07744737
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
Trial Treatment · Phase 2 · Changzhou No.2 People's Hospital
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing
Registry updated 2026-08-06
NCT07744750
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma
Trial Treatment · Phase 2 · Changzhou No.2 People's Hospital
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing
Registry updated 2026-08-06

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error